{"id":"capsaicin-1-oral-solution","safety":{"commonSideEffects":[{"rate":"null","effect":"Skin irritation"}]},"_chembl":{"chemblId":"CHEMBL294199","moleculeType":"Small molecule","molecularWeight":"305.42"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The activation of TRPV1 receptors by capsaicin triggers a signaling cascade that ultimately results in the release of substance P, a neurotransmitter involved in pain transmission. This leads to a reduction in pain perception. The exact mechanisms underlying capsaicin's analgesic effects are complex and multifaceted, involving both central and peripheral mechanisms.","oneSentence":"Capsaicin activates TRPV1 receptors, leading to the release of substance P and subsequent pain relief.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:48:59.095Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relief of pain associated with minor cuts, scrapes, and burns"}]},"trialDetails":[{"nctId":"NCT03511846","phase":"PHASE1","title":"Pain Biomarker Study","status":"ENROLLING_BY_INVITATION","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2018-03-21","conditions":"Migraine, Cluster Headache, Trigeminal Autonomic Cephalgia","enrollment":371},{"nctId":"NCT04704453","phase":"PHASE2","title":"Study to Evaluate the Interest of Qutenza in Patients With Head and Neck Cancer in Remission and With Sequelae Neuropathic Pain.","status":"COMPLETED","sponsor":"Institut Claudius Regaud","startDate":"2021-04-28","conditions":"Head and Neck Cancer","enrollment":13},{"nctId":"NCT04773184","phase":"","title":"Improving Diagnostic Standards in Dysphagia","status":"COMPLETED","sponsor":"University of Florida","startDate":"2021-04-27","conditions":"Dysphagia","enrollment":46},{"nctId":"NCT04470752","phase":"PHASE2","title":"Capsaicin for Post-stroke Dysphagia","status":"UNKNOWN","sponsor":"Georg Kägi, MD","startDate":"2021-08-24","conditions":"Dysphagia, Late Effect of Stroke","enrollment":82},{"nctId":"NCT02962050","phase":"","title":"Delineating Swallowing Impairment and Decline in ALS","status":"COMPLETED","sponsor":"University of Florida","startDate":"2017-05-31","conditions":"Amyotrophic Lateral Sclerosis","enrollment":109},{"nctId":"NCT05713019","phase":"NA","title":"ATP and P2X3 Receptor in Chronic Cough","status":"UNKNOWN","sponsor":"Imperial College London","startDate":"2023-02-28","conditions":"Cough","enrollment":20},{"nctId":"NCT02710110","phase":"EARLY_PHASE1","title":"Respiratory Strength Training in Persons With Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-04","conditions":"Amyotrophic Lateral Sclerosis","enrollment":50},{"nctId":"NCT04052178","phase":"NA","title":"Sensory Neuromodulation Protocol for the Treatment of Post-stroke Oropharyngeal Dysphagia.","status":"COMPLETED","sponsor":"Hospital de Mataró","startDate":"2016-02-10","conditions":"Swallowing Disorder, Dysphagia, Stroke","enrollment":36},{"nctId":"NCT02710162","phase":"EARLY_PHASE1","title":"Accurate Screening Tools for Dysphagia in Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-04","conditions":"Amyotrophic Lateral Sclerosis","enrollment":21},{"nctId":"NCT01494636","phase":"PHASE1","title":"The Safety, Tolerability, PK and PD of GSK2339345 in Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-10-17","conditions":"Cough","enrollment":31},{"nctId":"NCT01899768","phase":"PHASE2","title":"GSK2339345 Hypertussive Challenge Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-11","conditions":"Cough","enrollment":16},{"nctId":"NCT00692146","phase":"PHASE1","title":"Study to Investigate the Effects Single Oral Dose of AZD1386 (Capsaicin)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-01","conditions":"Capsaicin Evoked Pain, Heat Sensitivity","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Capsaicin 1% oral solution","genericName":"Capsaicin 1% oral solution","companyName":"Georg Kägi, MD","companyId":"georg-k-gi-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Capsaicin activates TRPV1 receptors, leading to the release of substance P and subsequent pain relief. Used for Relief of pain associated with minor cuts, scrapes, and burns.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}